✦ LIBER ✦

Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

✍ Scribed by Yoshikuni Mizuno; Nobuo Yanagisawa; Sadako Kuno; Mitsutoshi Yamamoto; Kazuko Hasegawa; Hideki Origasa; Hisayuki Kowa

Publisher: John Wiley and Sons
Year: 2003
Tongue: English
Weight: 103 KB
Volume: 18
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.10508

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment. © 2003 Movement Disorder Society

📜 SIMILAR VOLUMES

Randomized, double-blind, multicenter ev

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease

✍ Robert A. Hauser; Anthony H.V. Schapira; Olivier Rascol; Paolo Barone; Yoshikuni 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 1 views

## Abstract The objective of this study was to evaluate the efficacy and safety of pramipexole extended release (ER) administered once daily in early Parkinson's disease (PD). Pramipexole immediate release (IR) administered three times daily (TID) is an efficacious and generally well‐tolerated trea

Rotigotine transdermal patch in early Pa

Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole

✍ Nir Giladi; Babak Boroojerdi; Amos D. Korczyn; David J. Burn; Carl E. Clarke; An 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

## Abstract Rotigotine is a new, non‐ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine,

Botulinum toxin type A for drooling in P

Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study

✍ Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Mari 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gla

Comparison of desipramine and citalopram

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study

✍ David Devos; Kathy Dujardin; Isabelle Poirot; Caroline Moreau; Olivier Cottencin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants

Safety and efficacy of perampanel in adv

Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study

✍ Karla Eggert; David Squillacote; Paolo Barone; Richard Dodel; Regina Katzenschla 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

Squillacote, received compensation from Eisai for their site's conduct of the study. Drs. Barone, Lees, and Oertel received honoraria from Eisai as members of the Advisory Board of this study. Dr. Rascol has received unrestricted scientific grant and honoraria from Eisai for his advice to the compan

A double-blind randomized crossover tria

A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome

✍ Dr. Arthur S. Walters; Wayne A. Hening; Neil Kavey; Sudhansu Chokroverty; Steve 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

A double-blind randomized crossover study of 7.5 mg bromocriptine at bedtime versus placebo was conducted in 30-day phases (with a 2-week washout period between phases) in 6 patients with idiopathic restless legs syndrome. Five patients experienced partial subjective improvement in restlessness and